Compare DAIO & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAIO | CTXR |
|---|---|---|
| Founded | 1969 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 18.9M |
| IPO Year | 1995 | 2010 |
| Metric | DAIO | CTXR |
|---|---|---|
| Price | $3.92 | $0.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.22 | ★ $6.00 |
| AVG Volume (30 Days) | 144.5K | ★ 367.0K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $21,500,000.00 | N/A |
| Revenue This Year | $4.51 | N/A |
| Revenue Next Year | $30.29 | $147.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.16 | $0.48 |
| 52 Week High | $4.49 | $2.24 |
| Indicator | DAIO | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 59.81 | 45.13 |
| Support Level | $2.89 | $0.57 |
| Resistance Level | $4.10 | $0.74 |
| Average True Range (ATR) | 0.28 | 0.04 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 68.91 | 46.82 |
Data I/O Corp provides semiconductor programming, security provisioning, and intellectual property protection and management solutions used in electronics manufacturing with flash memory, microcontrollers, and flash memory-based intelligent devices as well as secure element devices, authentication devices and secure microcontrollers. It operates as a single segment entity, with the sole objective to design, manufacture, and sell programming solutions and Programming-as-a-Service (PaaS) to the world's various electronics manufacturers including OEMs, CMs and EMS companies. The company operate in three separate locations Redmond, Washington; Shanghai, China; and Munich, Germany.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.